查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2112827

全球人類微生物組市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Human Microbiome Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 205 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球人類微生物組市場預計將從2025年的15.1億美元成長至2034年的57.8億美元，2026年至2034年的複合年成長率（CAGR）為16.08%。全球人類微生物組市場正經歷快速成長，這主要得益於人們對微生物在人類健康中所起作用的研究不斷深入。人類微生物組與多種疾病相關，包括胃腸道疾病、代謝性疾病和免疫系統調節。人們對腸道環境重要性的認知不斷提高，以及對益生菌和基於微生物組的療法的需求不斷成長，正在推動市場擴張。此外，定序技術的進步也使得人們能夠更深入地了解微生物群落。

關鍵成長要素包括微生物組研究投入的增加，以及微生物組相關產品在醫療保健和營養領域的應用不斷拓展。製藥和生技公司正致力於開發針對多種疾病的微生物組標靶療法。個人化醫療和預防醫學的日益普及也促進了市場成長。此外，研究機構與產業相關人員之間的合作正在加速該領域的創新。

未來，隨著研發的持續推進和技術的進步，人類微生物組市場預計將顯著成長。標靶微生物組療法和診斷方法的開發有望拓展其臨床應用。在新興市場，健康意識的提高和醫療基礎設施的改善可能會創造新的機會。此外，監管的進步和標準化有望促進基於微生物組產品的商業化。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含多個關鍵組成部分，旨在幫助您全面了解市場環境。

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的關鍵促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：對主要市場參與企業進行詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。本報告深入分析了競爭動態以及主要參與者所採取的策略，提供了寶貴的見解。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新的投資機會。本部分重點在於潛在的成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球人類微生物組市場：依部位分類

  • 市場分析、洞察與預測
  • 消化道
  • 肺
  • 生殖腔
  • 皮膚
  • 其他部分

第5章：全球人類微生物組市場：依應用分類

  • 市場分析、洞察與預測
  • 治療
  • 診斷

第6章 全球人類微生物組市場：依疾病分類

  • 市場分析、洞察與預測
  • 感染疾病
  • 消化系統疾病
  • 內分泌/代謝疾病
  • 癌症
  • 中樞神經系統疾病
  • 其他疾病

第7章 全球人類微生物組市場：依產品分類

  • 市場分析、洞察與預測
  • 製藥
  • 補充
  • 診斷測試
  • 其他產品

第8章 全球人類微生物組市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和分銷通路合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Biohm Technologies
    • BioGaia
    • Biome Diagnostics
    • BiomeBank
    • Ferring
    • Intralytix
    • OptiBIoTix
    • Pendulum Therapeutics
    • Prescient Metabiomics
    • Seres Therapeutics
簡介目錄
Product Code: VMR11215790

The global human microbiome market size is expected to reach USD 5.78 Billion in 2034 from USD 1.51 Billion in 2025, growing at a CAGR of 16.08% during 2026-2034.The global human microbiome market is experiencing rapid growth due to increasing research on the role of microorganisms in human health. The human microbiome is linked to various conditions, including gastrointestinal disorders, metabolic diseases, and immune system regulation. Growing awareness about the importance of gut health and the rising demand for probiotic and microbiome-based therapies are driving market expansion. Additionally, advancements in sequencing technologies are enabling deeper insights into microbial communities.

Key growth drivers include increasing investments in microbiome research and the expanding applications of microbiome-based products in healthcare and nutrition. Pharmaceutical and biotechnology companies are focusing on developing microbiome-targeted therapies for various diseases. The rising popularity of personalized medicine and preventive healthcare is also contributing to market growth. Furthermore, collaborations between research institutions and industry players are accelerating innovation in this field.

Looking ahead, the human microbiome market is expected to grow significantly with ongoing research and technological advancements. The development of targeted microbiome therapies and diagnostics will expand clinical applications. Emerging markets are likely to offer new opportunities due to increasing health awareness and improving healthcare infrastructure. Additionally, regulatory advancements and standardization will support the commercialization of microbiome-based products.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Site

  • Digestive Tract
  • Lung
  • Reproductive Cavity
  • Skin
  • Other Sites

By Application

  • Therapeutics
  • Diagnostics

By Disease

  • Infectious Disease
  • Gastrointestinal Disease
  • Endocrine And Metabolic Diseases
  • Cancer
  • Central Nervous System Disorder
  • Other Diseases

By Product

  • Drugs
  • Supplements
  • Diagnostic Tests
  • Other Products

COMPANIES PROFILED

  • Archer Daniels Midland Company, Biohm Technologies, BioGaia, Biome Diagnostics, BiomeBank, Ferring, Intralytix, OptiBiotix, Pendulum Therapeutics, Prescient Metabiomics, Seres Therapeutics.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN MICROBIOME MARKET: BY SITE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Site
  • 4.2. Digestive Tract Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Reproductive Cavity Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Skin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Other Sites Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HUMAN MICROBIOME MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HUMAN MICROBIOME MARKET: BY DISEASE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Disease
  • 6.2. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Gastrointestinal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Endocrine And Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Central Nervous System Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HUMAN MICROBIOME MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Product
  • 7.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Diagnostic Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Other Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HUMAN MICROBIOME MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Site
    • 8.2.2 By Application
    • 8.2.3 By Disease
    • 8.2.4 By Product
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Site
    • 8.3.2 By Application
    • 8.3.3 By Disease
    • 8.3.4 By Product
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Site
    • 8.4.2 By Application
    • 8.4.3 By Disease
    • 8.4.4 By Product
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Site
    • 8.5.2 By Application
    • 8.5.3 By Disease
    • 8.5.4 By Product
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Site
    • 8.6.2 By Application
    • 8.6.3 By Disease
    • 8.6.4 By Product
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL HUMAN MICROBIOME INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Biohm Technologies
    • 10.2.2 BioGaia
    • 10.2.3 Biome Diagnostics
    • 10.2.4 BiomeBank
    • 10.2.5 Ferring
    • 10.2.6 Intralytix
    • 10.2.7 OptiBiotix
    • 10.2.8 Pendulum Therapeutics
    • 10.2.9 Prescient Metabiomics
    • 10.2.10 Seres Therapeutics